Back to Tirzepatide research
tirzepatide gip agonist other 2026-04-01 ClinicalTrials

Real-World Tirzepatide Effectiveness and Dosing in Obesity Patients

Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity

Background

Obesity is a complex chronic disease with significant health implications, and novel pharmacotherapies like tirzepatide have emerged as powerful treatment options. While controlled clinical trials have demonstrated remarkable efficacy, with some participants achieving up to 21% body weight reduction, there is a recognized gap in understanding its real-world effectiveness and optimal dosing patterns in routine clinical practice. This knowledge gap is crucial for translating trial results into broader patient benefits.

Study Design

Population
Adult patients with obesity in routine clinical practice.
Intervention
Tirzepatide, with real-world dosing patterns.
Outcome
Real-world effectiveness and optimal dosing patterns of tirzepatide.

tirzepatide gip agonist glp 1 agonist dose mentioned
Source: clinicaltrials:NCT07504172 · Ingested 2026-05-01 · Digest: gemini-2.5-flash